alprenolol   Click here for help

GtoPdb Ligand ID: 563

Synonyms: Atenenol®
Approved drug
alprenolol is an approved drug
Compound class: Synthetic organic
Comment: The approved drug alprenolol is a racemic mixture of the R and S isomers. We show the non-stereo structure to represent the mixture.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 41.49
Molecular weight 249.17
XLogP 2.84
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CCc1ccccc1OCC(CNC(C)C)O
Isomeric SMILES C=CCc1ccccc1OCC(CNC(C)C)O
InChI InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
InChI Key PAZJSJFMUHDSTF-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
3. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
5. Baker JG, Adams LA, Salchow K, Mistry SN, Middleton RJ, Hill SJ, Kellam B. (2011)
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
J Med Chem, 54 (19): 6874-87. [PMID:21870877]
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341]
7. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]
8. Baker JG, Hall IP, Hill SJ. (2004)
Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production.
Mol Pharmacol, 65 (4): 986-98. [PMID:15044629]
9. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025)
Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor.
Mol Pharmacol, 107 (11): 100081. [PMID:41289653]
10. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.
Br J Pharmacol, 112 (3): 911-9. [PMID:7921620]
11. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004)
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417]
12. Strosberg AD. (1997)
Structure and function of the beta 3-adrenergic receptor.
Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260]